NLRP3, the inflammasome and COVID-19 infection
Citation:
Yin M, Marrone L, Peace C.G, O'Neill L.A.J, NLRP3, the inflammasome and COVID-19 infection, QJM: An International Journal of Medicine, 116, 7, 2023, 502 - 507Download Item:
Abstract:
Severe coronavirus disease 2019 (COVID-19) is characterized by respiratory failure, shock or multiorgan dysfunction, often accompanied by systemic hyperinflammation and dysregulated cytokine release. These features are linked to the intense and rapid stimulation of the innate immune response. The NACHT, LRR and PYD domains-containing protein 3 (NLRP3) inflammasome is a central player in inflammatory macrophage activation which via caspase-1 activation leads to the release of the mature forms of the proinflammatory cytokines interleukin (IL)-1β and IL-18, and via cleavage of Gasdermin D pyroptosis, an inflammatory form of cell death. Here, we discuss the role of NLRP3 activation in COVID-19 and clinical trials currently underway to target NLRP3 to treat severe COVID-19.
Sponsor
Grant Number
Science Foundation Ireland (SFI)
(12/IA/1531
Author's Homepage:
http://people.tcd.ie/laoneillDescription:
PUBLISHED
Author: O'Neill, Luke
Sponsor:
Science Foundation Ireland (SFI)Type of material:
Journal ArticleCollections
Series/Report no:
QJM: An International Journal of Medicine;116;
7;
Availability:
Full text availableKeywords:
Severe coronavirus disease 2019 (COVID-19), respiratory failure, systemic hyperinflammationDOI:
http://dx.doi.org/10.1093/qjmed/hcad011Metadata
Show full item recordLicences: